Recent Updates
Recently added Catalysts

MEDIROM Healthcare Technologies Inc. American Depositary Share

MRMFDA catalysts, PDUFA dates & pipeline intelligence
$0.26
▼ -0.01 · -3.58%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MRM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.2452W HIGH $2.33
Volume
711.08 K
Value Traded
199.03 K
Short % Float
-
Days to Cover
1.0
-6.91%Week
-25.36%1 Month
-73.73%3 Month
-72.92%6 Month

Cash Data

Unlock MRM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.09 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
7.90 M
Float Shares
-
Insiders
-
Institutions
1.59%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every MRM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MRM Catalyst Timeline

Dated clinical, regulatory and corporate events for MEDIROM Healthcare Technologies Inc. American Depositary Share

Unlock the full MRM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MRM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all MRM historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the MRM pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MRM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every MRM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MRM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full MRM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in MRM for Q3 2026.
Unlock every fund holding MRM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MRM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MRM ownership
Insider and institutional ownership, quarter by quarter.

MRM Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
9.0K
Shares Sold Short
-69.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
65.4K
Avg Daily Volume
the average used for days to cover
Unlock MRM short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock MRM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MRM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MRM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MRM ranks across every disease it competes in

Competitive Position is a premium feature
See how MRM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MRM News

-MRM
Nov 18, 2026
MRMGeneral
▼ -3.6%today

MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request

MEDIROM Healthcare Technologies Inc. received a delisting notice from Nasdaq due to its failure to file the Annual Report on Form 20-F. The company has submitted a hearing request to appeal this determination, which temporarily stays the trading suspension. Despite filing the Annual Report, compliance with Nasdaq's requirements remains uncertain.

Read more →
-MRM
Jun 25, 2026
MRMGeneral

MEDIROM MOTHER Labs Expands Deployment of "REMONY®" Remote Health Monitoring System in JGSDF 8th Division

MEDIROM MOTHER Labs has received an additional order from the Japan Ground Self-Defense Force for its REMONY® remote health monitoring system. The deployment has expanded to three times the initial scale due to the system's effectiveness in heatstroke prevention and continuous operation without charging. The MOTHER Bracelet® tracks vital health metrics in real-time.

Read more →
-MRM
May 29, 2026
MRMGeneral
▼ -5%on this news

MEDIROM Healthcare Technologies Inc. Receives Notification from Nasdaq Related to Annual Report

MEDIROM Healthcare Technologies Inc. has received a notification from Nasdaq regarding non-compliance with listing rules due to late filing of its Form 20-F. The company is given 60 days to propose a compliance plan to address this issue. Currently, this notification does not impact the trading status of its American Depositary Shares. If accepted, the company could receive further time to achieve compliance, but risks losing its listing if it cannot meet Nasdaq's requirements.

Read more →
-MRM
May 28, 2026
MRMGeneral

MEDIROM Group Reports Q1 2026 Results

MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) reported positive performance for Q1 2026, highlighting a 7.7% year-over-year increase in Average Revenue Per Customer. The company is adopting a hybrid staffing model to enhance service quality and boost earnings for therapists, which aims to improve retention and align compensation with performance. Additionally, MEDIROM has partnered with Tools for Humanity to expand its World ID verification services, planning significant growth in operational scale across Japan. However, there was a noted decrease in total customers and salons compared to the previous year.

Read more →
-MRM
Apr 16, 2026
MRMGeneral

Annex A to Notice of Convocation Note This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original,

MEDIROM Healthcare Technologies Inc. will hold its 26th Ordinary General Meeting of Shareholders on May 29, 2026. Shareholders will vote on two key proposals: the approval of the financial statements for the 26th fiscal year and the re-election of four directors along with the election of one new director. The details of the proposals include necessary compliance with Japanese Companies Act requirements. Shareholders unable to attend in person can vote by proxy.

Read more →
-MRM
Feb 27, 2026
MRMGeneral
▼ -5.2%on this news

MEDIROM Launches Partnership with Tools for Humanity in February; Projects Approximately $39 Million in Income Before Income Taxes Over Two Years Following Expansion to 3,000 Nationwide Locations

MEDIROM Healthcare Technologies has entered a Master Service Agreement with Tools for Humanity, effective February 2, 2026. The partnership aims to expand MEDIROM's services to approximately 3,000 locations in Japan, potentially generating around $39 million in income before taxes over the next two years. The company currently operates over 150 locations with successful authentication performance.

Read more →
-MRM
Jan 30, 2026
MRMGeneral

MEDIROM Healthcare Technologies Inc. Announces December 2025 Key Performance Indicators (KPIs)

MEDIROM Healthcare Technologies Inc. has announced its December 2025 Key Performance Indicators, showcasing a total of 70,499 customers served and a record sales per customer of JPY 7,926. The company experienced a slight improvement in customer loyalty, with a repeat customer ratio of 77.8%. As part of future reporting, MEDIROM plans to shift from monthly operational updates to quarterly performance reports starting in fiscal year 2026. Additionally, the company launched a new health tech initiative aimed at enhancing mid- to long-term growth, though it has temporarily impacted treatment utilization rates.

Read more →
-MRM
Jan 23, 2026
MRMGeneral

MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations

MEDIROM Healthcare Technologies Inc. has formed a new Special Mission Team to promote the adoption of World ID across Japan through partnerships with Tools for Humanity and the World Foundation. The company plans to install Orb authentication devices at approximately 3,000 locations, including its Re.Ra.Ku wellness centers and other retail partners. The initiative aims to establish a standardized quality of services while expanding the use of their advanced identification technology nationwide.

Read more →
-MRM
Jan 8, 2026
MRMGeneral

World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration Re.Ra.Ku’s “Orb” Authentication Surpasses 20,000 Cumulative Verifications, Doubling in Approximately Two Months

MEDIROM Healthcare Technologies reported that its World ID authentication device, 'Orb', has surpassed 20,000 cumulative verifications, doubling in just two months. This growth was driven by a successful marketing campaign offering free shoulder massages at Re.Ra.Ku stores. The company plans to expand the installation of Orbs to 200 salons across Japan.

Read more →
-MRM
Dec 29, 2025
MRMGeneral

MEDIROM Partners with World on Technology Envisioned by Sam Altman and Alex Blania: Deploying “Proof of Human” Infrastructure throughout Japan

MEDIROM Healthcare Technologies has partnered with Tools for Humanity and World Foundation to implement Proof of Human technologies across Japan. This initiative aims to enhance online trust by allowing individuals to verify their humanity without disclosing personal information. The collaboration will leverage MEDIROM's extensive network of wellness locations and is expected to generate new revenue streams while contributing to the digital society.

Read more →
-MRM
Dec 28, 2025
MRMGeneral

World, Co-founded by Sam Altman and Alex Blania, Accelerates Expansion in Japan via MEDIROM Collaboration

MEDIROM Healthcare Technologies has announced that its collaboration with World has resulted in over 20,000 verifications of its 'Orb' authentication device at Re.Ra.Ku wellness salons across Japan. This milestone occurred in just two months, reflecting rapid user adoption and interest, particularly following a promotional campaign. MEDIROM plans to expand the installation of Orbs to 200 salons nationwide, enhancing access to this new technology aimed at facilitating Proof of Human authentication as part of a broader digital infrastructure initiative.

Read more →
-MRM
Dec 22, 2025
MRMGeneral

MEDIROM Healthcare Technologies Inc. Announces November 2025 Key Performance Indicators (KPIs)

MEDIROM Healthcare Technologies Inc. (MRM) reported robust key performance indicators for November 2025, highlighting a total of 67,800 customers served with a sales per customer figure of JPY 7,621. The customer repeat ratio also improved to 79.4%, reflecting a stable and loyal customer base. These metrics illustrate the Company's progress in its salon operation business and the overall positive trend in its customer engagement.

Read more →
-MRM
Dec 4, 2025
MRMGeneral

MEDIROM Mother Labs Partners with TD SYNNEX to Accelerate National Adoption of "MOTHER Bracelet" and "REMONY"

MEDIROM Healthcare Technologies Inc. has announced a distributor agreement with TD SYNNEX K.K. to bolster the adoption of its health-tech products, including the recharge-free MOTHER Bracelet and the REMONY health monitoring system. The collaboration seeks to leverage TD SYNNEX's extensive sales network to promote the use of these innovative tracking solutions across Japan. The MOTHER Bracelet operates continuously without the need for charging, providing vital health metrics while minimizing data loss. Meanwhile, REMONY enables centralized health monitoring, enhancing early detection of health issues and overall safety.

Read more →
-MRM
Dec 3, 2025
MRMGeneral

MEDIROM Healthcare Technologies Inc. Announces October 2025 Key Performance Indicators (KPIs)

MEDIROM Healthcare Technologies Inc. has announced its October 2025 Key Performance Indicators, revealing a total of 69,669 customers served and a sales per customer figure of JPY 7,445. Notably, the customer repeat ratio increased to 77.8%, reflecting a year-over-year improvement in customer loyalty. The company also reported cumulative contracts with 101 corporate insurance associations and over 11,000 users of its health guidance app, Lav. These indicators suggest solid growth in both customer engagement and the adoption of health tech services.

Read more →
-MRM
Oct 30, 2025
MRMGeneral
▲ +7.7%on this news

MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors Completion of Private Placement of New Shares as Part of Series A Round Valued at 9 Billion

MEDIROM MOTHER Labs Inc. has successfully completed a private placement of new shares as part of its Series A round, valued at 9 billion. This capital investment comes from internal investors, including the company's President and CEO. The funds will be used to strengthen their capital base and enhance the development of their health tech products, particularly the MOTHER Bracelet. The initiative aims to boost decision-making and foster a field-driven management approach as the company seeks sustainable growth and the introduction of new healthcare solutions.

Read more →
-MRM
Oct 29, 2025
MRMGeneral
▼ -21%on this newsshared move

MEDIROM to Launch New Treasury Strategy Utilizing Cryptocurrency Aimed at incentivize large-scale vital data collection

MEDIROM Healthcare Technologies Inc. has announced a new treasury strategy that incorporates cryptocurrency, specifically holding Worldcoin (WLD) and Ethereum (ETH) as reserve assets. The initiative aims to incentivize the collection of vital data from users of its MOTHER Bracelet by distributing WLD to participants with specific medical conditions. This move is part of a larger strategy to diversify business operations and mitigate financial risks, with ongoing analysis and transparency regarding asset management being emphasized by the company.

Read more →
-MRM
Oct 28, 2025
MRMGeneral

More than 10,000 people receive verified World IDs at Medirom locations "MEDIROM is a location partner for the World Network, co-founded by Sam Altman and Alex Blania,to promote domestic adoption of proof of human techno

MEDIROM Healthcare Technologies Inc. announced that it has surpassed 10,000 verified World IDs at its wellness salons in Japan as of October 23, 2025. The company is partnering with the World Network, co-founded by Sam Altman and Alex Blania, to promote the technology that confirms individuals' humanness rather than their identities. With plans to install an advanced verification system, the Orb, in 200 stores, MEDIROM aims to leverage this technology to enhance services and support revenue growth.

Read more →
-MRM
Oct 21, 2025
MRMGeneral

MEDIROM Healthcare Technologies Inc. Reports Financial Results for the Six Months Ended June 30, 2025 and Provides Corporate Update

MEDIROM Healthcare Technologies Inc. has released its interim financial results for the six months ending June 30, 2025. The report highlights the company's developments and financial stability as it continues operations and expansion in the holistic health services sector, particularly in Japan. The company also provides insights into their HealthTech initiatives and updates on strategic business operations.

Read more →
-MRM
Oct 20, 2025
MRMGeneral

MEDIROM Healthcare Technologies Inc. Announces September 2025 Key Performance Indicators (KPIs)

MEDIROM Healthcare Technologies Inc. announced its Key Performance Indicators for September 2025, reporting that it served 72,236 customers, an increase in operational efficiency from the previous year. The sales per customer have risen to JPY 7,498, exceeding the estimated industry average of JPY 4,806. The company's customer repeat ratio stands at 76.9%, suggesting strong customer loyalty. Additionally, the company continues to expand its health guidance program, further enhancing its market position.

Read more →
-MRM
Oct 9, 2025
MRMGeneral

MEDIROM MOTHER Labs Inc. Decides to Make an Investment from Internal Investors

MEDIROM MOTHER Labs Inc. announced a private placement of new shares in its Series A financing round, achieving a valuation of JPY9 billion. The investment comes from key management members, including the President and CEO, aiming to enhance decision-making and management effectiveness. This capital increase is expected to support the development of the upgraded MOTHER Bracelet and improve market strategies. The initiative reflects a commitment to expand the company's health-tech offerings domestically and internationally.

Read more →

About MEDIROM Healthcare Technologies Inc. American Depositary Share

1,051 employees medirom.co.jp
BIOPHARMAWATCH ELITE
Trade the next MRM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime